Lineage Cell Therapeutics
LCTX
108 hedge funds and large institutions have $56.4M invested in Lineage Cell Therapeutics in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
13% more funds holding
Funds holding: 96 → 108 (+12)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.79% less ownership
Funds ownership: 43.08% → 42.29% (-0.79%)
11% less capital invested
Capital invested by funds: $63.2M → $56.4M (-$6.78M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$152K |
| 2 |
WG
Winton Group
London,
United Kingdom
|
+$133K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$109K |
| 4 |
Morgan Stanley
New York
|
+$99.4K |
| 5 |
JP Morgan Chase
New York
|
+$88.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$1.15M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$484K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$154K |
| 4 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$142K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$92.3K |
LCTX Hedge Fund Activity: Q4 2019 in Review
108 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2019, worth a combined $56.4M — down 11% from $63.2M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LCTX positions and 9 closed out — a net gain of 12 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was Defender Capital, adding an estimated $152K. The largest seller was Axa, exiting entirely with an estimated $1.15M sold.
- 108 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2019, up from 96 in Q3 2019.
- Funds reported $56.4M of Lineage Cell Therapeutics stock for Q4 2019, down 11% quarter-over-quarter.
- 21 funds opened new Lineage Cell Therapeutics positions in Q4 2019 and 9 closed out, a net change of +12 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2019 was Defender Capital, an estimated $152K added.
- The largest Lineage Cell Therapeutics seller in Q4 2019 was Axa, an estimated $1.15M sold.
Based on aggregated 13F filings for Q4 2019.